Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Carroll

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Urology|May 12, 2004
Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer programPeter Iversen, Manfred P Wirth, William A See, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 13, 2019
Proteinuria Reduction as a Surrogate End Point in Trials of IgA NephropathyAliza Thompson, Kevin Carroll, Lesley A Inker, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 24, 2022
Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents-post hoc analyses of the ASCEND-ND and ASCEND-D trialsAjay K Singh, Finnian R McCausland, Brian L Claggett, et al.
The Journal of Urology|July 20, 2002
Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer programWilliam A See, Manfred P Wirth, David G McLeod, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 21, 2021
Study design and baseline characteristics of patients on dialysis in the ASCEND-D trialAjay K Singh, Allison Blackorby, Borut Cizman, et al.
The New England Journal of Medicine|November 10, 2025
Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 TrialVlado Perkovic, Hernán Trimarchi, Vladimir Tesar, et al.
The New England Journal of Medicine|November 5, 2021
Daprodustat for the Treatment of Anemia in Patients Undergoing DialysisAjay K Singh, Kevin Carroll, Vlado Perkovic, et al.
The New England Journal of Medicine|November 5, 2021
Daprodustat for the Treatment of Anemia in Patients Not Undergoing DialysisAjay K Singh, Kevin Carroll, John J V McMurray, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 5, 2021
The ASCEND-ND trial: study design and participant characteristicsVlado Perkovic, Allison Blackorby, Borut Cizman, et al.
JAMA Internal Medicine|April 4, 2022
Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical TrialAjay K Singh, Borut Cizman, Kevin Carroll, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Urology|May 12, 2004
Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer programPeter Iversen, Manfred P Wirth, William A See, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 13, 2019
Proteinuria Reduction as a Surrogate End Point in Trials of IgA NephropathyAliza Thompson, Kevin Carroll, Lesley A Inker, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 24, 2022
Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents-post hoc analyses of the ASCEND-ND and ASCEND-D trialsAjay K Singh, Finnian R McCausland, Brian L Claggett, et al.
The Journal of Urology|July 20, 2002
Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer programWilliam A See, Manfred P Wirth, David G McLeod, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 21, 2021
Study design and baseline characteristics of patients on dialysis in the ASCEND-D trialAjay K Singh, Allison Blackorby, Borut Cizman, et al.
The New England Journal of Medicine|November 10, 2025
Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 TrialVlado Perkovic, Hernán Trimarchi, Vladimir Tesar, et al.
The New England Journal of Medicine|November 5, 2021
Daprodustat for the Treatment of Anemia in Patients Undergoing DialysisAjay K Singh, Kevin Carroll, Vlado Perkovic, et al.
The New England Journal of Medicine|November 5, 2021
Daprodustat for the Treatment of Anemia in Patients Not Undergoing DialysisAjay K Singh, Kevin Carroll, John J V McMurray, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 5, 2021
The ASCEND-ND trial: study design and participant characteristicsVlado Perkovic, Allison Blackorby, Borut Cizman, et al.
JAMA Internal Medicine|April 4, 2022
Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical TrialAjay K Singh, Borut Cizman, Kevin Carroll, et al.
Pageof 6